WebThe International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients... WebWe identified age (≤65 vs 66-75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic …
IPSS-R Cytogenetic risk groups*,** - MDS Foundation
WebFeb 11, 2024 · However, the IPSSWM score is based upon measurements at diagnosis, not at first treatment. This reduces their utility, as scores are likely to change over time. The Registry plans to use the 2024 revised IPSSWM2 going forward. Watch and wait • WM patients can remain on active surveillance (commonly known as ‘watch and wait’) for WebJul 5, 2011 · Forty-three patients with symptomatic WM that was untreated or pretreated with 1 line of chemotherapy received rituximab 375 mg/m 2 intravenously on day 1 and fludarabine 25 mg/m 2 and cyclophosphamide 250 mg/m 2 intravenously on days 2 through 4. FCR was repeated every 28 days for up to 6 courses. RESULTS: herman habermann
Response and survival for primary therapy combination regimens …
WebFeb 3, 2024 · Age > 65 years, gender, MYD88 status, rituximab refractoriness, IPSSWM score, baseline IgM > 4,000 mg/dl or higher than the median value, Hb < 11 g/dl or less than the median value, platelet less than 100 × 10 9 /l, and the presence of enlarged lymph nodes or spleen were not associated with PFS, as reported in Table 3. WebSep 1, 2024 · WM is an extremely rare HM in the Peruvian population, 38 times less frequent than in Caucasians. Most patients have a high IPSSWM score. Although most patients did not use Rituximab, the OS was good considering the high IPSSWM score. WebIn Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the IPSSWM score as a prognostic factor for OS and PFS. There is an unmet need to improve access to recom … herman gundert malayalam